US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles
A warrant for Netanyahu’s arrest was requested. But no decision was made about whether to issue it
CLAIM: The International Criminal Court issued an arrest warrant for Israeli Prime Minister Benjamin2024-05-21Wang and Hsieh Clinch Women's Doubles Title at Roland Garros
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21China's Chen, Fan Labor to WTT Singapore Smash Crowns
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21Chinese Woman Astronaut Sets New Record
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21Colton Herta shows speed as Honda fights back in penultimate Indy 500 practice session
INDIANAPOLIS (AP) — Colton Herta and Andretti Global showed Monday that the Honda teams at the India2024-05-21DAILY MAIL COMMENT: Israel must beware all
The world had been waiting with deep foreboding to see how Tehran would respond to Israel's air stri2024-05-21
atest comment